Pfizer (PFE) : Aviance Capital Partners scooped up 45 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 98,319 shares of Pfizer which is valued at $3,439,199.Pfizer makes up approximately 1.21% of Aviance Capital Partners’s portfolio.
Other Hedge Funds, Including , King Luther Capital Management Corp reduced its stake in PFE by selling 1,266 shares or 0.04% in the most recent quarter. The Hedge Fund company now holds 2,987,650 shares of PFE which is valued at $104,507,997. Pfizer makes up approx 0.98% of King Luther Capital Management Corp’s portfolio.Geneva Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 6,529 additional shares and now holds a total of 200,519 shares of Pfizer which is valued at $7,048,243. Pfizer makes up approx 0.13% of Geneva Advisors’s portfolio.United Bank Va boosted its stake in PFE in the latest quarter, The investment management firm added 2,775 additional shares and now holds a total of 35,768 shares of Pfizer which is valued at $1,318,051. Pfizer makes up approx 1.24% of United Bank Va’s portfolio.Hermes Investment Management Ltd boosted its stake in PFE in the latest quarter, The investment management firm added 73,600 additional shares and now holds a total of 290,731 shares of Pfizer which is valued at $10,681,457. Pfizer makes up approx 0.21% of Hermes Investment Management Ltd’s portfolio.Chesley Taft Associates boosted its stake in PFE in the latest quarter, The investment management firm added 371 additional shares and now holds a total of 290,404 shares of Pfizer which is valued at $10,669,443. Pfizer makes up approx 1.06% of Chesley Taft Associates’s portfolio.
Pfizer opened for trading at $35 and hit $35.27 on the upside on Tuesday, eventually ending the session at $35.09, with a gain of 0.72% or 0.25 points. The heightened volatility saw the trading volume jump to 1,69,57,889 shares. Company has a market cap of $212,844 M.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.